Jörg Cammenga
11 – 20 of 51
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Precisionsmedicin standard vid flera hematologiska sjukdomar
(
- Contribution to journal › Article
-
Mark
Clinical and genomic characterization of patients diagnosed with the provisional entity Acute myeloid leukemia with BCR-ABL1, a Swedish population-based study
(
- Contribution to journal › Article
- 2020
-
Mark
Real-world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged ≥ 60 years
(
- Contribution to journal › Letter
-
Mark
The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting
(
- Contribution to journal › Article
- 2019
-
Mark
Hif-1α Deletion May Lead to Adverse Treatment Effect in a Mouse Model of MLL-AF9-Driven AML
(
- Contribution to journal › Article
-
Mark
Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period
(
- Contribution to journal › Letter
- 2018
-
Mark
A new genetic tool to improve immune-compromised mouse models : Derivation and CRISPR/Cas9-mediated targeting of NRG embryonic stem cell lines
(
- Contribution to journal › Article
-
Mark
Acute myeloid leukemia in very old patients
(
- Contribution to journal › Article
- 2017
-
Mark
Induction of the 5S RNP–Mdm2–p53 ribosomal stress pathway delays the initiation but fails to eradicate established murine acute myeloid leukemia
(
- Contribution to journal › Article
-
Mark
Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NFκB-dependent differentiation of AML cells
(
- Contribution to journal › Article